Literature DB >> 11567764

Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT.

A Nurkka1, H Ahman, M Yaich, J Eskola, H Käyhty.   

Abstract

We studied the immunogenicity of two octavalent pneumococcal (Pnc) conjugate vaccines; Pnc polysaccharides (PS) of serotypes 3, 4, 6B, 9V, 14, 18C, 19F, and 23F were conjugated to diphtheria or tetanus toxoid (PncD and PncT, respectively). Fifty healthy Finnish infants were vaccinated at the ages of 2, 4, 6, and 15 months with either PncD or PncT. Serum IgG antibodies to the vaccine serotypes were analysed by enzyme-linked immunosorbent assay (EIA). All eight PSs induced a significant antibody response both after the primary series and after the booster. Response to PncD was higher for PSs 3, 9V, 14 and 18C and to PncT for serotype 4. Salivary IgA and IgG anti-Pnc antibodies were measured for serotypes 4, 6B, 9V, 14, 18C, and 19F. Mucosal antibodies were found rarely after the primary series but in a greater proportion after the booster. In conclusion, both vaccines were immunogenic.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567764     DOI: 10.1016/s0264-410x(01)00250-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Effects of sample collection and storage methods on antipneumococcal immunoglobulin A in saliva.

Authors:  A Nurkka; J Obiero; H Käyhty; J A G Scott
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

Review 2.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

3.  Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.

Authors:  Nina Ekström; Heidi Ahman; Jouko Verho; Jukka Jokinen; Merja Väkeväinen; Terhi Kilpi; Helena Käyhty
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysaccharide of type 14 and pneumococcal surface adhesin A (PsaA) in children.

Authors:  B Simell; T Kilpi; H Käyhty
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

5.  Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy.

Authors:  Nina Ekström; Heidi Ahman; Arto Palmu; Sinikka Grönholm; Terhi Kilpi; Helena Käyhty
Journal:  Clin Vaccine Immunol       Date:  2013-05-08

Review 6.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

Review 7.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.

Authors:  Nina Ekström; Merja Väkeväinen; Jouko Verho; Terhi Kilpi; Helena Käyhty
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

9.  Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.

Authors:  Anu Nurkka; Mika Lahdenkari; Arto A I Palmu; Helena Käyhty
Journal:  BMC Infect Dis       Date:  2005-05-27       Impact factor: 3.090

Review 10.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.

Authors:  Maria Deloria Knoll; Daniel E Park; T Scott Johnson; Subash Chandir; Bareng Aletta S Nonyane; Laura Conklin; Katherine E Fleming-Dutra; Jennifer D Loo; David Goldblatt; Cynthia G Whitney; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.